Immediate Impact
1 from Science/Nature 81 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
2024 Standout
Works of Athanasios Karampeazis being referenced
Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study
2013
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Athanasios Karampeazis | 240 | 219 | 15 | 24 | 26 | 310 | |
| Ramón Barceló | 152 | 156 | 29 | 47 | 27 | 282 | |
| D. Natale | 249 | 105 | 38 | 43 | 22 | 324 | |
| Silvia Catanese | 226 | 98 | 37 | 91 | 28 | 362 | |
| Hyunho Kim | 151 | 89 | 21 | 55 | 33 | 298 | |
| Cheuk Hong Leung | 190 | 197 | 35 | 38 | 35 | 367 | |
| Frédéric Bigot | 208 | 135 | 14 | 80 | 33 | 335 | |
| Suzanna Bota | 169 | 187 | 16 | 93 | 20 | 312 | |
| Yu‐Jen Hsu | 210 | 78 | 14 | 145 | 37 | 280 | |
| Kentaro Masuhiro | 133 | 78 | 14 | 17 | 21 | 358 | |
| John Conibear | 115 | 152 | 8 | 30 | 28 | 332 |
All Works
Loading papers...